Industry

BOSTON–(BUSINESS WIRE)–Abacus Insights, a healthcare technology leader with the only cloud-based data transformation platform built specifically for health plans, is rolling out a suite of solutions that revolutionizes how payers can leverage data for faster and better decision making. Abacus Insights has introduced solutions that sort, bundle and continually update validated, transformed data to serve … [Read more…]

In partnership with the University of Melbourne, the restoration of this unique keystone species, which was hunted aggressively to extinction, holds promise of ecosystem restoration for Tasmania DALLAS–(BUSINESS WIRE)–Colossal Biosciences, a breakthrough genetic engineering and de-extinction company, announces it has started the de-extinction of the thylacine, a beloved Australian marsupial that was eradicated by human … [Read more…]

FREMONT, Calif.–(BUSINESS WIRE)–Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced $40 million in Series C equity and debt financing. The round was led by Advent Life Sciences and also included returning investors New Enterprise Associates (NEA), Future Fund, Vertex Healthcare, Gilde … [Read more…]

Stressed farmed animals pose a significant public health risk, doctors say WASHINGTON–(BUSINESS WIRE)–The Physicians Committee for Responsible Medicine, a national public health nonprofit of more than 17,000 doctor members, filed an amicus brief with the U.S. Supreme Court on Monday, Aug. 15, in support of California’s Proposition 12, a law establishing confinement standards for pigs … [Read more…]

First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that a supplemental New Drug Application (sNDA) for LYNPARZA in … [Read more…]

First PARP inhibitor to demonstrate clinical benefit in combination with a new hormonal agent irrespective of homologous recombination repair (HRR) gene mutations WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca’s supplemental New Drug Application (sNDA) for LYNPARZA® (olaparib) in combination with abiraterone and prednisone or prednisolone has been accepted and granted Priority Review in the US for the treatment of … [Read more…]

Restore Moves Up From No. 426 in 2021 to No. 411 in 2022 on the Inc. 5000 Ranking of America’s Fastest-Growing Private Companies AUSTIN, Texas–(BUSINESS WIRE)–Today, Inc. revealed that Restore Hyper Wellness (Restore), the leading provider of proactive wellness services, ranked No. 411 on its annual Inc. 5000 list, the most prestigious ranking of the … [Read more…]

PORTOLA VALLEY, Calif.–(BUSINESS WIRE)–TransMed7, LLC announced today that the “First in Human” clinical case of the commercial production version of a Heron™ XPS device (a member of the new Heron™ family of vacuum-assisted, Single Insertion / Multiple Collection (SIMC®) Soft Tissue Biopsy devices) was successfully performed by Dr. Edgar Staren, a surgical oncologist with the … [Read more…]

AUSTIN, Texas & LONDON–(BUSINESS WIRE)–Babylon Holdings Limited (NYSE: BBLN) (“Babylon” or the “Company”), one of the world’s fastest-growing digital healthcare companies, released a statement yesterday addressing the M&A speculation and a more than 20% increase in the Company’s stock price at one point during the trading day that led to the New York Stock Exchange’s … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “High Potency APIs Global Market Opportunities And Strategies To 2031” report has been added to ResearchAndMarkets.com’s offering. The global high potency APIs market reached a value of nearly $19,772.2 million in 2021, having grown at a compound annual growth rate (CAGR) of 5.2% since 2016. The market is expected to grow from $19,772.2 … [Read more…]